Morgan Stanley thinks this little-known autoimmune biotech stock can surge more than 40%
[ad_1]
Kyverna began trading on the Nasdaq on Feb. 8, when it jumped 56% to reach a market cap of $1.4 billion.
[ad_2]
Source link
[ad_1]
Kyverna began trading on the Nasdaq on Feb. 8, when it jumped 56% to reach a market cap of $1.4 billion.
[ad_2]
Source link
/cloudfront-us-east-2.images.arcpublishing.com/reuters/YZ47A4D6VFJLNFI2ZNR3VERXB4.jpg){kind=small}
